Phase 3RecruitingINTERVENTIONAL
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
ClinicalTrials.gov · NCT07253285 · Registry updated: 2026-09-30
- Condition / research focus
- Overweight; Obesity
- Sponsor
- Novo Nordisk A/S
- Countries with listed sites
- Australia · Austria · Belgium · Bulgaria · China · Colombia · Croatia · Denmark · Hungary · India · Israel · Italy · Malaysia · Mexico · Netherlands · Poland · Portugal · Romania · Serbia · Slovakia · Spain · Sweden · Taiwan · Thailand · United Kingdom · United States
- Registry dates and results
- Start: 2026-01-08. Completion: 2033-09-20 (may be estimated). No results posted in this registry response.
Products and interventions (4)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Cagrilintide (drug)
- Semaglutide (drug)
- Placebo cagrilintide (drug)
- Placebo semaglutide (drug)
Where the study takes place — 121 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.